Ventyx Biosciences, Inc. (VTYX)
| Market Cap | 158.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -152.52M |
| Shares Out | 70.71M |
| EPS (ttm) | -2.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,545,636 |
| Open | 2.270 |
| Previous Close | 2.280 |
| Day's Range | 2.240 - 2.360 |
| 52-Week Range | 1.670 - 11.480 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 8.40 (+275.0%) |
| Earnings Date | Nov 7, 2024 |
About VTYX
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflamm... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for VTYX stock is "Buy." The 12-month stock price forecast is $8.4, which is an increase of 275.00% from the latest price.
News
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ad...
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvi...
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a br...
Ventyx Biosciences Announces Departure of Chief Financial Officer
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a br...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ad...
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024
Dow Edges Lower; Ventyx Biosciences Shares Plummet
U.S. stocks were mostly higher toward the end of trading, while the Dow Jones index traded slightly lower on Monday.
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
Ventyx Biosciences Inc VTYX stock is trading lower on Monday.
VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, y...
VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (NASDAQ:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, y...
VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to submit your information by visiting https://www.bfalaw.com/cases/ventyx...
VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses
NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/v...
VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/v...
VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/v...
BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/v...
VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/...
STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/...
VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/v...
VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/...
VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors
NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/...
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a ran...
Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Martin Auster - Chief Financial Officer Raju Mohan - Founder and Chief Executive Of...
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a ran...